An Ann Arbor company has launched a product to research the main functional receptor for viral entry, or the part of the cell wall that lets a virus in, for COVID-19.
Swift Biosciences recently launched a new ACE2 Swift Normalase Amplicon Panel. ACE2, a receptor protein in human cells, has been identified as a key receptor for COVID-19 host cell entry. The study of the protein holds keys to understanding transmission, infection rates, and genetic variants that may play a role in susceptibility and severity. It could also make advancements in precision medicine and personalized treatments for COVID-19.
“The ACE2 SNAP panel is an important part of ongoing research into the SARS-CoV-2 host cell entry,” says Jordan RoseFigura, head of amplicon development at Swift. “Sequencing ACE2 has the potential to provide insight into disease outcome and facilitate further investigations. We developed our panel to optimize ACE2 sequencing data and accommodate many research studies. Combining this design with our SNAP workflow allows scientists to sequence ACE2 from a wide variety of sample types.”
The panel relies of Swift’s design of a single-tube polymerase chain reaction (PCR), which quickly makes millions of copies of a DNA sample, allowing scientists to study it. The company’s workflow generates these DNA libraries from low-input quantities of DNA. Its products lend themselves to automation and scalable results. Data analysis and interpretation is also now available through Swift.
Swift works in the commercialization of DNA and RNA Library Preparation Kits. The company offers research tools for studying cancer and inherited and infectious diseases. It also develops diagnostic tools and treatments.